The relationship between Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBD) represents one of the most clinically and pathologically complex intersections in the spectrum of 4R tauopathies. While these disorders were historically described as distinct entities, accumulating evidence demonstrates significant clinical, pathological, and genetic overlap, leading to the recognition of a spectrum of disorders rather than strictly separable diseases.
The PSP-CBD overlap syndrome presents unique challenges for clinicians and researchers, as patients may exhibit features of both disorders simultaneously or transition between clinical phenotypes over time. This overlap has profound implications for diagnosis, prognostic counseling, clinical trial design, and therapeutic development.
Initially, PSP and CBD were described as distinct clinical syndromes with characteristic pathological features:
Modern understanding has evolved to recognize these as related disorders within the 4R tauopathy spectrum:
Both PSP and CBD demonstrate significant overlap in their clinical presentations[1]:
| Feature | PSP | CBD | Overlap |
|---|---|---|---|
| Parkinsonism | Prominent | Asymmetric, prominent | Both show parkinsonian features |
| Cognitive dysfunction | Frontal executive | Cortical, language | Both develop cognitive decline |
| Axial rigidity | Prominent (cockroach posture) | Limb rigidity | Both show rigidity |
| Gait impairment | Early, prominent | Variable, late | Both ultimately affected |
| Oculomotor dysfunction | Vertical gaze palsy | Variable | Overlapping but not identical |
The PSP presenting with corticobasal syndrome (PSP-CBS) represents the most well-characterized overlap phenotype[2]:
Clinical Characteristics:
Distinguishing Features from Classic PSP:
Distinguishing Features from Classic CBD:
A notable phenomenon in the overlap spectrum is the potential for clinical phenotype transition over time:
Both PSP and CBD demonstrate 4R tau pathology, but with distinct patterns[3]:
PSP Pathological Hallmarks:
CBD Pathological Hallmarks:
Shared Features:
The distribution of tau pathology differs between PSP and CBD, explaining the clinical differences:
| Brain Region | PSP | CBD |
|---|---|---|
| Brainstem | Severe (midbrain, pontine nuclei) | Variable |
| Basal ganglia | Severe (STN, GP, SN) | Moderate |
| Cortex | Moderate (frontal > other) | Severe (frontoparietal) |
| Cerebellum | Moderate | Variable |
Recent advances in cryo-electron microscopy have revealed distinct tau filament structures[4]:
These structural differences support the concept of distinct "tau strains" while acknowledging the clinical overlap.
Genetic studies have identified significant overlap in risk factors for PSP and CBD[5]:
MAPT H1 Haplotype:
Other Shared Risk Loci:
While significant overlap exists, some genetic factors may modify the phenotype:
CSF biomarker profiles show considerable overlap but some discriminative features[6]:
| Biomarker | PSP | CBD | Notes |
|---|---|---|---|
| Total tau | ↑ | ↑↑ | Higher in CBD |
| p-tau181 | Normal/↑ | ↑↑ (with AD) | Higher in CBD with AD co-pathology |
| p-tau217 | Normal | Variable | May detect AD co-pathology |
| NfL | ↑ | ↑↑ | Higher in CBD |
| GFAP | ↑ | ↑ | Similar elevation |
Key Insight: The combination of biomarkers (NfL + p-tau181 + Aβ42) achieves approximately 82% accuracy for differentiating PSP from CBD.
Shared Imaging Features:
Differentiating Features:
Modern tau PET ligands show differential binding patterns[7]:
The Movement Disorder Society criteria for PSP and CBD acknowledge the overlap[8]:
PSP Diagnostic Criteria:
CBD Diagnostic Criteria:
Challenge: Features supporting one diagnosis may be present in the other, leading to diagnostic uncertainty.
A systematic approach to evaluating suspected PSP-CBD overlap:
Management approaches for PSP-CBD overlap are similar to both disorders[9]:
Pharmacological Approaches:
Non-Pharmacological:
The overlap has implications for therapeutic development:
The PSP-CBD overlap has significant implications for clinical research:
Current research priorities include:
Shared therapeutic strategies for both conditions:
Ling H, Massey LA, Lees AJ. Atypical parkinsonism. Handbook of Clinical Neurology. 2023. ↩︎
Armstrong MJ, Litvan I, Lang AE, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013. ↩︎
Dickson DW, Ahmed Z, Alghamdi A, et al. Neuropathology of corticobasal degeneration. Acta Neuropathol. 2010. ↩︎
Fitzpatrick AWP, Falcon B, He S, et al. Cryo-EM structures of tau filaments from Alzheimer's disease brain. Nature. 2017. ↩︎
Chen JA, Chen Q, Yang G, et al. Shared genetic architecture between progressive supranuclear palsy and corticobasal degeneration. Brain. 2021. ↩︎
Blommer R, Zetterberg H, van der Flier WM, et al. Combined CSF biomarker analysis for differential diagnosis of atypical parkinsonism. Neurology. 2024. ↩︎
Tau PET imaging in 4R tauopathies. Nat Rev Neurol. 2021. ↩︎
Höglinger GU, Respondek G, Stamelou M, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017. ↩︎
Stamelou M, Höglinger GU. Review: Therapeutic approaches to progressive supranuclear palsy. Expert Opin Ther Targets. 2019. ↩︎